<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276196</url>
  </required_header>
  <id_info>
    <org_study_id>DC2014ELIX001</org_study_id>
    <nct_id>NCT02276196</nct_id>
  </id_info>
  <brief_title>Effect of LIXIsenatide on the Renal System</brief_title>
  <acronym>ELIXIRS</acronym>
  <official_title>A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based
      therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4
      inhibitors, may hold promise in preventing the onset and progression of diabetic kidney
      disease. However, the potential renoprotective effects of these agents, that are believed to
      be effectuated &quot;beyond glucose control&quot;, have not been sufficiently detailed in human
      diabetes.

      Therefore, the present study aims to explore the mechanistic and clinical effects of GLP-1
      receptor agonists on renal physiology and biomarkers in patients with type 2 diabetes.

      Forty patients with insulin-treated type 2 diabetes will undergo an eight week intervention
      with lixisenatide or insulin glulisine in order to assess changes in the outcome parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>ml/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal damage, measured by urine biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <description>enzyme immuno assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal tubular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. percentage (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body anthropometrics: body weight, height, body mass index, waist circumference</measure>
    <time_frame>8 weeks</time_frame>
    <description>kilogram, meters, centimeters</description>
  </other_outcome>
  <other_outcome>
    <measure>Body fat content</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. percentage (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycemic variables</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. mmol/l, mmol/mol</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid spectrum</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. mmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. nmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Systemic hemodynamic variables</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. ml/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>beat per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. count</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. augmentation index</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Diabetic Nephropathy</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Glucagon-Like Peptide 1</condition>
  <arm_group>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lixisenatide will be administered subcutaneously, once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glulisine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glulisine will be administered subcutaneously, once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <description>GLP-1 receptor agonist</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <other_name>Lyxumia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Insulin analogue</description>
    <arm_group_label>Insulin glulisine</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes (HbA1c: 6.5-10.0% or 48-86 mmol/mol)

          -  Stable treatment with basal insulin glargine (dose ±20%) and metformin or basal
             insulin glargine (dose ±20%) alone for at least 3 months

          -  Fasting plasma glucose &lt;10 mmol/L or the use of &gt;50 units of basal insulin glargine

          -  Females must be post-menopausal

          -  Caucasian

          -  Age: 35 - 75 years

          -  Body Mass Index: &gt;25 kg/m2

          -  Hypertension should be under control, i.e. &lt;140/90 mmHg, and treated with an
             angiotensin-converting enzyme inhibitor or angiotensin-II-receptor blocker for at
             least 3 months.

          -  Albuminuria should be treated with an angiotensin-converting enzyme inhibitor (ACE-I)
             or angiotensin-II-receptor blocker (ARB) for at least 3 months.

        Exclusion Criteria:

          -  Current/chronic use of the following medication: thiazolidinediones, sulfonylurea
             derivatives, GLP-1 receptor agonists, dipeptidyl peptidase (DPP)-4 inhibitors,
             glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics,
             antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors. Subjects
             on diuretics, will only be excluded when these drugs cannot be stopped for the
             duration of the study.

          -  Chronic use of non-steroidal anti-inflammatory drugs will not be allowed, unless used
             as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports
             injury, head-ache or back ache). However, no such drugs can be taken within a
             time-frame of 2 weeks prior to renal-testing

          -  Hypoglycemia unawareness based on investigator judgment

          -  History of severe hypoglycemia that required emergency hospital treatment within 3
             months prior to screening

          -  Estimated GFR &lt;60 mL/min/1.73m2 (determined by the Modification of Diet in Renal
             Disease (MDRD) study equation)

          -  Pregnancy

          -  Current urinary tract infection and active nephritis

          -  Recent (&lt;6 months) history of cardiovascular disease, including: acute coronary
             syndrome, chronic heart failure (New York Heart Association grade II-IV), stroke or
             transient ischemic neurologic disorder

          -  Complaints compatible with or established gastroparesis, neurogenic bladder and/or
             incomplete bladder emptying (as determined by ultrasonic bladder scan)

          -  Active liver disease or a 3-fold elevation of liver enzymes (aspartate
             aminotransferase/alanine aminotransferase) at screening

          -  History of or actual pancreatic disease

          -  History of or actual malignancy (except basal cell carcinoma)

          -  History of or actual severe mental disease

          -  Substance abuse (alcohol: defined as &gt;4 units/day)

          -  Allergy to any of the agents used in the study

          -  Individuals who are investigator site personnel, directly affiliated with the study,
             or are immediate (spouse, parent, child, or sibling, whether biological or legally
             adopted) family of investigator site personnel directly affiliated with the study

          -  Inability to understand the study protocol or give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VU Universtiy Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.H.H. Kramer</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

